About the Company
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ETTX News
Pivotal bioVenture Partners Fund I, L.P.'s Net Worth
This is based on reported shares across multiple companies, which include Inozyme Pharma, Inc., Entasis Therapeutics Holdings Inc., and Akouos, Inc..
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
CERo Therapeutics Holdings Inc CERO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Plc Astrazeneca's Net Worth
Plc Astrazeneca has an estimated net worth of $812 Million. This is based on reported shares across multiple companies, which include Viela Bio, Inc., Aevi Genomic Medicine, Inc., PhaseBio ...
DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy ...
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
Cerevel Therapeutics Holdings Inc Ordinary Shares CERE
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
CERo Therapeutics Holdings, Inc. (CERO)
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected ...
CERo Therapeutics Holdings, Inc. (CEROW)
SOUTH SAN FRANCISCO, Calif., March 07, 2024--CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T ...
Loading the latest forecasts...